Access Industries Takes 19.99% Stake in OnKure Therapeutics, Secures Board Seat in $40M Strategic Investment
OKUR has more than doubled off its 52-week low of $1.7.
Summary
Access Industries, led by Len Blavatnik, has acquired a 19.99% stake in OnKure Therapeutics for approximately $40 million through a private placement, securing a board seat and providing critical capital.
Key Events · Ownership and Investor Activity · OKUR
-
Major Strategic Investment
Access Industries, led by Len Blavatnik, invested approximately $40 million in OnKure Therapeutics as part of a private placement.
-
Significant Ownership Stake
The investment results in Access Industries holding a 19.99% beneficial ownership stake in the company, comprising both common stock and pre-funded warrants.
-
Board Representation Secured
Access Industries secured a board designation right, leading to the appointment of Dr. Liam Ratcliffe, Head of Biotechnology at Access Industries, to the company's board of directors.
-
Addresses Going Concern
This substantial capital infusion is a critical component of the $150 million private placement, directly addressing the 'going concern' warning disclosed in the company's recent 10-K filing.
Analysis · OKUR · Life Sciences
This Schedule 13D filing details the specific participation of Access Industries, an entity controlled by Len Blavatnik, in OnKure Therapeutics' recently announced $150 million private placement. Access Industries invested approximately $40 million, acquiring 3.99 million shares and pre-funded warrants for 5.64 million shares, resulting in a 19.99% beneficial ownership stake. This significant capital infusion, representing a substantial portion of the company's market capitalization, is a crucial development following the company's recent 10-K filing which raised substantial doubt about its ability to continue as a going concern. The investment, which includes a board designation right and the appointment of Dr. Liam Ratcliffe to the board, provides a vital lifeline and signals strong institutional confidence in the company's future, addressing immediate financial stability concerns.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OKUR was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.7M. The 52-week trading range was $1.70 to $4.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.